Kallikrein

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.

Multiple companies are developing kallikrein inhibitor therapies for various routes of delivery to provide an alternative treatment for patients with diabetic macular edema rather than the traditional treatment of anti-VEGF injections.